Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Long-Term Investments: 2021-2024

Historic Long-Term Investments for C4 Therapeutics (CCCC) over the last 4 years, with Dec 2024 value amounting to $22.4 million.

  • C4 Therapeutics' Long-Term Investments fell 72.62% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 72.62%. This contributed to the annual value of $22.4 million for FY2024, which is 20.17% down from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Long-Term Investments is $22.4 million, which was down 20.17% from $28.0 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Long-Term Investments ranged from a high of $142.2 million in FY2021 and a low of $22.4 million during FY2024.
  • Its 3-year average for Long-Term Investments is $37.1 million, with a median of $28.0 million in 2023.
  • Data for C4 Therapeutics' Long-Term Investments shows a maximum YoY slumped of 57.13% (in 2022) over the last 5 years.
  • C4 Therapeutics' Long-Term Investments (Yearly) stood at $142.2 million in 2021, then tumbled by 57.13% to $61.0 million in 2022, then tumbled by 54.06% to $28.0 million in 2023, then fell by 20.17% to $22.4 million in 2024.